These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 32727149)

  • 21. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.
    Garimella PS; Fink HA; Macdonald R; Wilt TJ
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007360. PubMed ID: 19821408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial.
    Gotoh M; Kamihira O; Kinukawa T; Ono Y; Ohshima S; Origasa H;
    BJU Int; 2005 Sep; 96(4):581-6. PubMed ID: 16104914
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Silodosin versus naftopidil in the treatment of premature ejaculation: A prospective multicenter trial.
    Sato Y; Otani T; Amano T; Araki T; Kondou N; Matsukawa M; Tobe M; Haga K; Uchida K; Honma I
    Int J Urol; 2017 Aug; 24(8):626-631. PubMed ID: 28627033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel naftopidil-related derivatives and their biological effects as alpha1-adrenoceptors antagonists and antiproliferative agents.
    Huang J; He F; Huang M; Liu X; Xiong Y; Huang Y; Zhu L; Yang Y; Xu X; Yuan M
    Eur J Med Chem; 2015; 96():83-91. PubMed ID: 25874333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [LUTS in BPH patients : Comparison of silodosin versus tamsulosin, naftopidil, alfuzosin and placebo for the treatment of lower urinary tract symptoms].
    Praus F; Miernik A
    Urologe A; 2019 Jul; 58(7):795-798. PubMed ID: 31143977
    [No Abstract]   [Full Text] [Related]  

  • 26. Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia.
    Yamanishi T; Yasuda K; Kamai T; Tsujii T; Sakakibara R; Uchiyama T; Yoshida K
    Int J Urol; 2004 Jul; 11(7):501-9. PubMed ID: 15242359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Post-Marketing Surveillance of Silodosin in Patients with Benign Prostatic Hyperplasia and Poor Response to Existing Alpha-1 Blockers: The SPLASH Study.
    Takahashi H; Kubono S; Taneyama T; Kuramoto K; Mizutani H; Tanaka N; Yoshida M
    Drugs R D; 2019 Mar; 19(1):47-55. PubMed ID: 30607819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical effects of naftopidil on nocturia associated with benign prostatic hyperplasia].
    Sugino Y; Fukuzawa S; Takeuchi H; Taki Y; Hashimura T; Soeda T; Araki I
    Hinyokika Kiyo; 2003 Aug; 49(8):445-9. PubMed ID: 14518379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. α1D/A-adrenoceptor antagonist naftopidil for the male lower urinary tract symptoms associated with benign prostatic hyperplasia: efficacy of dose increase therapy.
    Yamaguchi S; Osanai H; Numata A; Watanabe M; Kakizaki H
    Int J Urol; 2013 May; 20(5):513-9. PubMed ID: 23078534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Naftopidil induces apoptosis in malignant mesothelioma cell lines independently of α1-adrenoceptor blocking.
    Masachika E; Kanno T; Nakano T; Gotoh A; Nishizaki T
    Anticancer Res; 2013 Mar; 33(3):887-94. PubMed ID: 23482758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Piperazine-based Alpha-1 AR Blocker, Naftopidil, Selectively Suppresses Malignant Human Bladder Cells via Induction of Apoptosis.
    Nakagawa YU; Nagaya H; Miyata T; Wada Y; Oyama T; Gotoh A
    Anticancer Res; 2016 Apr; 36(4):1563-70. PubMed ID: 27069132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Efficacy and Safety of Naftopidil Treatment for Patients with Benign Prostatic Hyperplasia and Hypertension: A Prospective, Open-Label Study.
    Chung MS; Yoon BI; Lee SH
    Yonsei Med J; 2017 Jul; 58(4):800-806. PubMed ID: 28540994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictive factors for the effect of the α1-D/A adrenoceptor antagonist naftopidil on subjective and objective criteria in patients with neurogenic lower urinary tract dysfunction.
    Takeda M; Homma Y; Araki I; Kakizaki H; Yamanishi T; Yokota T; Gotoh M; Igawa Y; Seki N; Takei M; Yoshida M; Sugaya K; Nishizawa O;
    BJU Int; 2011 Jul; 108(1):100-7. PubMed ID: 21062392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of intrathecal injection of tamsulosin and naftopidil, alpha-1A and -1D adrenergic receptor antagonists, on bladder activity in rats.
    Sugaya K; Nishijima S; Miyazato M; Ashitomi K; Hatano T; Ogawa Y
    Neurosci Lett; 2002 Aug; 328(1):74-6. PubMed ID: 12123863
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A comparative study assessing clinical effects of naftopidil and tamsulosin hydrochloride on benign prostatic hyperplasia].
    Hayashi T; Sakai Y; Saito K; Arai G; Hyochi N; Suzuki M; Masuda H; Kawakami S; Okuno T; Kobayashi T; Kageyama Y; Kihara K
    Hinyokika Kiyo; 2002 Jan; 48(1):7-11. PubMed ID: 11868386
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Naftopidil, a novel alpha1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1-adrenoceptors.
    Takei R; Ikegaki I; Shibata K; Tsujimoto G; Asano T
    Jpn J Pharmacol; 1999 Apr; 79(4):447-54. PubMed ID: 10361884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A comparative study assessing clinical effects of naftopidil and tamsulosin hydrochloride on benign prostatic hyperplasia with overactive bladder].
    Kosugi S; Ikemoto I; Furuta A; Shimomura T; Kiyota H; Suzuki Y; Kishimoto K; Egaway S; Torii S; Shirai H; Takeuchi H; Abe K
    Nihon Hinyokika Gakkai Zasshi; 2007 Jul; 98(5):691-9. PubMed ID: 17682448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pharmacological properties of naftopidil, a drug for treatment of the bladder outlet obstruction for patients with benign prostatic hyperplasia].
    Ikegaki I
    Nihon Yakurigaku Zasshi; 2000 Aug; 116(2):63-9. PubMed ID: 10976457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of naftopidil on nocturia after failure of tamsulosin.
    Oh-oka H
    Urology; 2008 Nov; 72(5):1051-5. PubMed ID: 18817955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of silodosin and naftopidil in the treatment of bladder dysfunction in the spontaneously hypertensive rat.
    Saito M; Shimizu S; Ohmasa F; Oikawa R; Tsounapi P; Dimitriadis F; Kinoshita Y; Satoh K
    Neurourol Urodyn; 2013 Apr; 32(4):393-8. PubMed ID: 22907830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.